Latham & Watkins Advises Caris Life Sciences on IPO

Caris Life Sciences® (Caris), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has announced the pricing of its initial public offering of 23,529,412 shares of its common stock, at a public offering price of US$21 per share. In addition, Caris has granted the underwriters a 30-day option to purchase up to an additional 3,529,411 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Select Market on June 18, 2025, under the ticker symbol “CAI.” The offering is expected to close on June 20, 2025, subject to customary closing conditions.

Latham & Watkins LLP is advising Caris Life Sciences in the offering with a corporate team led by New York partners Nathan Ajiashvili and Alison Haggerty, and Austin partner Samer Zabaneh, with associates Sandy Kugbei, Jie Lin Nai, Akina Newbraugh, and Radley Gillis.